Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic...

Area of Science:

• Hematology
• Transplantation Medicine
• Biostatistics

Background:

• The Charlson Comorbidity Index (CCI) has limitations in predicting outcomes for allogeneic hematopoietic cell transplantation (HCT) due to low capture rates of patients with comorbidities.
• Existing comorbidity assessment tools do not fully capture the specific complexities relevant to HCT patients.

Purpose of the Study:

• To develop and validate a novel comorbidity index specifically tailored for predicting outcomes in allogeneic HCT.
• To refine the definition of comorbidities using pretransplant laboratory data and identify additional HCT-specific comorbidities.

Main Methods:

• A cohort of 1055 patients undergoing HCT was used, with data randomly split into training and validation sets.
• Comorbidities were weighted based on prognostic significance using Cox proportional hazard models.
• A new index was developed and validated against the CCI.

Main Results:

• The new index captured a significantly higher percentage of patients with comorbidities (62%) compared to the CCI (12%).
• The novel index demonstrated superior survival prediction accuracy over the CCI, evidenced by higher likelihood ratios (23.7 vs. 7.1) and c-statistics (0.661 vs. 0.561).
• The index proved effective in predicting nonrelapse mortality and overall survival.

Conclusions:

• A new, simple comorbidity index offers a valid and reliable method for assessing pretransplant comorbidities in HCT patients.
• This index enhances the prediction of nonrelapse mortality and survival, surpassing the predictive capabilities of the CCI.
• The developed index is a valuable tool for clinical trial stratification and pre-HCT patient counseling.